Straits Times Index
3,313.03 -9.05 (-0.27%) Nikkei
39,167.32 +129.16 (+0.33%) Hang Seng
18,034.04 -332.91 (-1.81%) FTSE 100
8,228.48 -16.89 (-0.20%) Bitcoin USD
68,227.54 -1,505.10 (-2.16%) CMC Crypto 200
1,422.91 -23.76 (-1.64%)
TEVA Jan 2025 4.000 call
- Business Wire
Teva to Present at the Goldman Sachs 45th Annual Global Healthcare Conference
TEL AVIV, Israel, June 04, 2024--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that Richard Francis, Teva's President and CEO, will present at the Goldman Sachs 45th Annual Global Healthcare Conference on Tuesday, June 11, 2024. The presentation will begin at 8:00 A.M. Eastern Time.
- Zacks
TEVA Stock Rises 135% in a Year: What's Driving the Recovery?
TEVA expects its newer drugs, Austedo, Uzedy and Ajovy, as well as a stable generics business, to help revive top-line growth in future quarters.
- Business Wire
New Data Provide Schizophrenia Treatment Insights into Switching to UZEDY® (risperidone) Extended-Release Injectable Suspension from Invega Sustenna® (paliperidone palmitate)
TEL AVIV, Israel & PARSIPPANY, N.J., June 01, 2024--Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced the presentation of seven studies from its long-acting injectable (LAI) schizophrenia research program. Presentations include data informing clinical strategies for switching patients to UZEDY, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia
